These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 33142878)

  • 1. In Vitro and In Vivo Models for Evaluating the Oral Toxicity of Nanomedicines.
    Lama S; Merlin-Zhang O; Yang C
    Nanomaterials (Basel); 2020 Oct; 10(11):. PubMed ID: 33142878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grouping of orally ingested silica nanomaterials via use of an integrated approach to testing and assessment to streamline risk assessment.
    Di Cristo L; Ude VC; Tsiliki G; Tatulli G; Romaldini A; Murphy F; Wohlleben W; Oomen AG; Pompa PP; Arts J; Stone V; Sabella S
    Part Fibre Toxicol; 2022 Dec; 19(1):68. PubMed ID: 36461106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantitative Analysis of Gastrointestinal Physiology for Better Prediction of Oral Drug Absorption and Interaction].
    Shirasaka Y
    Yakugaku Zasshi; 2020; 140(5):599-608. PubMed ID: 32378658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine-based commercial formulations: current developments and future prospects.
    Thapa RK; Kim JO
    J Pharm Investig; 2023; 53(1):19-33. PubMed ID: 36568502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicines - Tiny particles and big challenges.
    Marques MRC; Choo Q; Ashtikar M; Rocha TC; Bremer-Hoffmann S; Wacker MG
    Adv Drug Deliv Rev; 2019; 151-152():23-43. PubMed ID: 31226397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period.
    Yaju Y; Kataoka Y; Eto H; Horiuchi S; Mori R
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009328. PubMed ID: 24277681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
    Sudsakorn S; Bahadduri P; Fretland J; Lu C
    Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
    Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
    Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
    Wang Y; Cai R; Chen C
    Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics.
    Choi YH; Han HK
    J Pharm Investig; 2018; 48(1):43-60. PubMed ID: 30546919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
    Rivera VM
    Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.